Cervical Cancer Screening.

Journal Article (Journal Article;Review)

Cervical cancer screening in the United States has accompanied profound decreases in cancer incidence and mortality over the last half century. Two screening strategies are currently endorsed by US-based guideline groups: (1) triennial cytology for women aged 21 to 65 years, and (2) triennial cytology for women aged 21 to 29 years followed by cytology plus testing for high-risk human papillomavirus types every 5 years for women aged 30 years and older. Providing women with affordable, easily accessible screening, follow-up of abnormal tests, and timely treatment will result in the greatest impact of screening on cervical cancer incidence and mortality.

Full Text

Duke Authors

Cited Authors

  • Sawaya, GF; Huchko, MJ

Published Date

  • July 2017

Published In

Volume / Issue

  • 101 / 4

Start / End Page

  • 743 - 753

PubMed ID

  • 28577624

Pubmed Central ID

  • PMC6585416

Electronic International Standard Serial Number (EISSN)

  • 1557-9859

Digital Object Identifier (DOI)

  • 10.1016/j.mcna.2017.03.006


  • eng

Conference Location

  • United States